Furthermore, KRAS mutations are also used as major prognostic biomarkers for therapies that target the EGFR in patients with metastatic colorectal cancer, as cancer bearing KRAS mutations are reportedly unresponsive to anti- EGFR monoclonal antibodies such as cetuximab and panitumumab3,11–14. This evidence concerns the gene EGFR and metastatic colorectal cancer.